Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance (empagliflozin), has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult chronic kidney disease (CKD). This development expands the drug’s therapeutic applications in China.
EMPA-KIDNEY Study Outcomes
The approval is supported by the EMPA-KIDNEY study, which demonstrated significant benefits of Jardiance over a placebo in CKD patients. The study showed a 28% reduction in the relative risk of kidney disease progression or cardiovascular death events, and a 14% decrease in the relative risk of hospitalization for any reason. The safety profile of Jardiance was found to be consistent with previous reports, further validating its use in CKD treatment.
Jardiance’s Expanded Indications
Jardiance has already been approved by the NMPA for the treatment of heart failure and type 2 diabetes (T2D), marking it as a versatile therapy for multiple chronic conditions. The drug’s new indication for CKD further solidifies its role in managing a broader range of health issues.- Flcube.com
